## Contents

**Monthly Volume 14 Number 11 November 24, 2023**

### ORIGINAL ARTICLE

**Retrospective Study**

<table>
<thead>
<tr>
<th>445</th>
<th>Analysis of clinicopathological features and prognostic factors of breast cancer brain metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chen YR, Xu ZX, Jiang LX, Dong ZW, Yu PF, Zhang Z, Gu GL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>459</th>
<th>Clinical study of standard residual liver volume and transient elastography in predicting poor prognosis of patients after hemihepatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yue ZQ, Zhang P, Yan S, Ju LL, Wang HX, Yuan LX, Chen L, Wu JZ, Cao YL</td>
</tr>
</tbody>
</table>

### Observational Study

<table>
<thead>
<tr>
<th>471</th>
<th>System describing surgical field extension associated with flap reconstruction after resection of a superficial malignant soft tissue tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sakamoto A, Noguchi T, Matsuda S</td>
</tr>
</tbody>
</table>

### Basic Study

<table>
<thead>
<tr>
<th>479</th>
<th>Computational exploration of the significance of COPS6 in cancer: Functional and clinical relevance across tumor types</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Wang SL, Zhuo GZ, Wang LP, Jiang XH, Liu GH, Pan YB, Li YR</td>
</tr>
</tbody>
</table>

### META-ANALYSIS

<table>
<thead>
<tr>
<th>504</th>
<th>Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zhang ZH, Bao YW, Zhao YJ, Wang JQ, Guo JT, Sun SY</td>
</tr>
</tbody>
</table>

### SCIENTOMETRICS

<table>
<thead>
<tr>
<th>518</th>
<th>Bibliometric analysis of the global research status and trends of mechanotransduction in cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Zhang YZ, Li MZ, Wang GX, Wang DW</td>
</tr>
</tbody>
</table>

### CASE REPORT

<table>
<thead>
<tr>
<th>535</th>
<th>Autoimmune diabetes from pembrolizumab: A case report and review of literature</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bhandari H, Khalid F, Bodla ZH, Muhammad T, Du D, Meghal T</td>
</tr>
</tbody>
</table>

| 544 | Calcitriol induced hypercalcemia - a rare phenomenon in lung cancer: A case report |
|-----|**********************************************************************************|
|     | Prakash A, Khalid F, Alalwan A, Bader H, Du D, Meghal T                                                                        |
ABOUT COVER
Peer Reviewer of World Journal of Clinical Oncology, Bene Ekine-Afolabi, PhD, Research Associate, Department of Biomedical Sciences, School of Health, Sport and Biosciences, University of East London, Stratford-London E15 4LZ, Universal Scientific Education & Research Network (USERN), London, United Kingdom.
dcr@zeabtherapeutic.com

AIMS AND SCOPE
The primary aim of World Journal of Clinical Oncology (WJCO, World J Clin Oncol) is to provide scholars and readers from various fields of oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.
WJCO mainly publishes articles reporting research results and findings obtained in the field of oncology and covering a wide range of topics including art of oncology, biology of neoplasia, breast cancer, cancer prevention and control, cancer-related complications, diagnosis in oncology, gastrointestinal cancer, genetic testing for cancer, gynecologic cancer, head and neck cancer, hematologic malignancy, lung cancer, melanoma, molecular oncology, neurooncology, palliative and supportive care, pediatric oncology, surgical oncology, translational oncology, and urologic oncology.

INDEXING/ABSTRACTING
The WJCO is now abstracted and indexed in PubMed, PubMed Central, Emerging Sources Citation Index (Web of Science), Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCO as 2.8; IF without journal self cites: 2.8; 5-year IF: 3.0; Journal Citation Indicator: 0.36.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Xiang-Di Zhang; Production Department Director: Xu Guo; Editorial Office Director: Xu Guo.
Basic Study

Computational exploration of the significance of COPS6 in cancer: Functional and clinical relevance across tumor types

Shi-Lin Wang, Guang-Zheng Zhuo, Li-Ping Wang, Xiang-Hu Jiang, Guo-Hong Liu, Yun-Bao Pan, Yi-Rong Li

Abstract

BACKGROUND
The COP9 signalosome subunit 6 (COPS6) has been implicated in cancer progression, while its precise role in most types of cancer remains elusive.

AIM
To investigate the functional and clinical relevance of COPS6 across various tumor types using publicly available databases.

METHODS
We used R software and online analysis databases to analyze the differential expression, prognosis, mutation and related functions of COPS6 in pan-cancer.

RESULTS
Differential expression analysis and survival analysis demonstrated that COPS6 was highly expressed and associated with high-risk profiles in the majority of cancer types. Possible associations between COPS6 expression level and prognostic outcomes were found using data from public databases. Mutational analysis revealed that missense mutations were the predominant type of COPS6 mutation. Additionally, positive correlations were identified between COPS6 expression level and tumor mutational burden and microsatellite instability in most types of cancer. Immune infiltration analysis demonstrated a negative correlation between COPS6 expression level and CD8+ T cell infiltration in certain types of cancer. The correlation between COPS6 expression level and cancer-associated fibroblast infiltration exhibited heterogeneity, in which a positive correlation was found in head and neck squamous cell carcinoma and tenosynovial giant cell tumor, and a negative correlation was identified in diffuse large...
B-cell lymphoma and thymoma. The correlation between COPS6 expression level and macrophage infiltration was closely related to macrophage type. Gene co-expression and enrichment analysis highlighted transcription elongation factor B polypeptide 2 and G protein pathway suppressor 1 were significantly and positively associated with COPS6 expression level. These genes were predominantly involved in processes, such as ubiquitin-mediated proteolysis and human immunodeficiency virus 1 infection.

CONCLUSION
In conclusion, this study systematically explored the significance of COPS6 across different tumor types, providing a solid foundation for considering COPS6 as a novel biomarker in cancer research.

Key Words: COPS6; Biomarker; Tumor mutational burden; Immune infiltration; Prognostic analysis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The COP9 signalosome subunit 6 COPS6 has been implicated in several cancer types. However, its precise role in most cancer types remains poorly understood. Therefore, we aimed to investigate the function of COPS6 in various tumor types. Through our analysis, we discovered that COPS6 is highly expressed and associated with high-risk profiles in most cancers. Meanwhile, COPS6 expression was positively correlated with tumor mutation burden, microsatellite instability, and immune infiltration of the tumor microenvironment. Our findings suggest that COPS6 could be a potential biomarker for cancer research. Our study contributes to the understanding of the role of COPS6 in cancer progression and highlights the clinical applications.

INTRODUCTION
According to recent data from the American Cancer Society, it is projected that the United States will witness 1958310 new cancer cases and 609820 cancer-related deaths by 2023[1]. While there has been a 1.5% decrease in cancer mortality rates between 2019 and 2020, with an overall decline of 33% since 1991, the incidence of breast cancer, prostate cancer, and uterine cancer is on the rise, imposing potential challenges to the future progress. Furthermore, these types of cancer demonstrate significant disparities in mortality rates among different ethnic groups. Conversely, gastric cancer, esophageal cancer, and cervical cancer have shown downward mortality rates, while lung cancer, colorectal cancer (CRC), and female breast cancer continue to exhibit gradually upward mortality rates[2,3]. These trends underscore the persisting challenges caused by cancer. Hence, it is imperative to explore new targets for early diagnosis and personalized treatment, as emphasized by previous studies[4,5]. The identification and analysis of novel pan-cancer genes can provide valuable insights into the intricate process of tumorigenesis. Public databases and online analysis tools, such as The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) provide convenient access to comprehensive cancer-relevant databases across diverse cancer types, enabling in-depth pan-cancer analysis[6,7].

The COP9 signalosome (COPS) is a multiprotein complex involved in protein degradation, transcriptional activation, signal transduction, and tumor progression[8,9]. COPS6, together with its dimerization partner COPS5, plays a crucial role in the activation process of deneddylase activity by embedding into the core of the helical bundle[10]. While the literature has reported the mechanisms of COPS6 in human malignancies, such as cervical cancer, papillary thyroid carcinoma (THCA), CRC, breast cancer, lung adenocarcinoma (LUAD), and glioblastoma, the available information is incomplete and the underlying mechanisms remain to be fully elucidated[11].

The present study aimed to comprehensively elucidate the involvement and clinical implications of COPS6 in many diverse types of cancer. This involved an in-depth analysis of differential expression patterns, prognostic values, gene mutations, immune infiltration, correlation analysis, and functional enrichment assessment, utilizing publicly available databases.

MATERIALS AND METHODS
Differential expression analysis
GEPIA2 (http://gepia2.cancer-pku.cn/#degenes) was utilized for analysis of RNA-seq expression data collected from TCGA and Genotype-Tissue Expression (GTEx) projects, enabling differential analysis, correlation analysis, and survival analysis[12]. Genetic difference analysis was conducted using TIMER2 (http://timer.cistrome.org/)[13]. COPS6
expression level in tumor and normal samples was compared using R (ver. 4.0.3), TIMER2, and GEPIA2. Box plots were generated using the ggpubr R (ver. 4.0.3) package, and differential expression of COPS6 in TCGA samples was determined using the Wilcoxon test. For cancers lacking normal controls in the TCGA database, the TIMER2 website was employed for differential analysis of the COPS6 gene.

For protein analysis, UALCAN online portal (http://ualcan.path.uab.edu/analysis-prot.html) was utilized to examine gene, protein, methylation, and phosphorylation differences[14]. UALCAN facilitated the comparison of differential expression of COPS6 protein between tumor and normal tissues. Age-differential expression data was obtained using the limma and ggpubr R packages, while clinical stage differential expression of COPS6 was obtained from the GEPIA2 website.

**Survival analysis**
To perform survival analysis for COPS6, the "Survival Map" feature of GEPIA2 was utilized. This facilitated plotting heatmaps representing overall survival (OS) and disease-free survival (DFS) using data from TCGA database. Forest plots, encompassing OS, progression-free interval (PFI), disease-specific survival (DSS), and disease-free interval (DFI), were generated using the survival and forestplot R packages in association with Cox analysis.

In March 2022, the pan-cancer data were downloaded from the TCGA database, including tumor stage, tumor grade, survival time, and mutation information. The raw data were preprocessed by the R programming language. The survminer R package was utilized to generate Kaplan-Meier survival curves for OS, PFI, DSS, and DFI, with a significance level set at P < 0.05.

**Genetic alteration analysis**
For mutation analysis, cBioPortal (https://www.cbioportal.org/) was utilized[15]. In this study, the "Quick Search" feature of cBioPortal was employed to examine the mutation frequency, type, copy number alteration (CNA), and structural variants of TCGA tumors involving COPS6. Furthermore, information related to the specific mutation sites and three-dimensional (3D) structure of the COPS6 protein was collected. To assess the impact of COPS6 alterations on patient survival, "TCGA, PanCancer Atlas" and "Compassion/Survival" modes were utilized to plot OS, DSS, DFS, and progression-free survival curves for TCGA cases with and without COPS6 alterations, respectively, using the log-rank test.

**Immune infiltration analysis**
To investigate immune infiltration, TIMER2 web server was used. In the present study, the presence of CD8+ T cells, cancer-associated fibroblasts, natural killer (NK) cells, and macrophages was assessed using the "Immune" module. To explore the relationship between immune inflammatory cells and COPS6 expression, multiple algorithms were utilized, including XCELL, EPIC, TIMER, MCP COUNTER, CIBERSORT-ABS, TIDE, CIBERSORT, and QUANTISEQ. P values and partial correlation values were obtained using the purity-adjusted Spearman's rank correlation test to quantify the strength and significance of the observed correlations.

**Enrichment analysis and correlation analysis**
The "Similar Gene Detection" module on the GEPIA2 website was utilized to identify the top 100 genes correlated with COPS6. Further analysis using the "correlation analysis" module on the same website narrowed down the selection to the top 5 genes with the highest correlation coefficients. Heatmap analysis of these genes was conducted using the "Gene_Corr" module available on the TIMER2 website. The purity-adjusted Spearman's rank correlation test was applied to obtain P-values and partial correlation values.

For protein-protein interaction (PPI) analysis, the STRING database (https://string-db.org/) was employed[16]. COPS6 was submitted to the database to generate a PPI network with Homo sapiens as the reference organism. The network settings included a full network type, evidence-based network edges, experiments as active interaction sources, a minimum required interaction score of high confidence (0.7), and a maximum number of interactors shown in the 1st and 2nd shells.

To identify overlapping genes between the COPS6-related genes obtained from the GEPIA2 and STRING, a Venn diagram was generated using GraphPad Prism 9.0.0 software (GraphPad Software Inc., San Diego, CA, United States). The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the DAVID database (https://david.ncifcrf.gov/home.jsp) with involvement of parameters, such as "OFFICIAL_GENE_SYMBOL", "Homo sapiens", and "functional annotation chart".

**RESULTS**

**COPS6 expression level varied in various tumors**
The overview of the pan-cancer analysis workflow is shown in Figure 1A. Differential expression analysis of COPS6 was conducted on TCGA data using R programming language. Significant differential expression (P < 0.05) of COPS6 was found between normal and tumor tissues in several cancer types, including bladder cancer (BLCA), breast invasive carcinoma (BRCA), cholangiocarcinoma (CHOL), colon adenocarcinoma (COAD), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC),
Figure 1 Differential expression analysis of COP9 signalosome subunit 6 in pan-cancer. A: Overview of the pan-cancer analysis workflow; B:
The relationship between COPS6 expression level and immune infiltration was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

To compare protein expression level of COPS6 among multiple types of cancer, protein expression differences between tumor and normal tissues from the CPTAC database on the UALCAN website were compared. The results revealed the elevated expression level of COPS6 in hepatocellular carcinoma and clear cell renal cell carcinoma tissues (Figure 2A). Additionally, the relationship between COPS6 expression level and clinical parameters was investigated using the GEPIA2 website, indicating the presence of association between COPS6 expression level and clinical stages of LUAD, KICH, KIRP, and LIHC (P < 0.05) (Figure 2B). Furthermore, significantly upregulated COPS6 expression level in ESCA, LUAD, and LUSC in cases who aged < 65-years-old in TCGA database was found, whereas COPS6 expression level was reduced in KIRC (P < 0.05) (Figure 2C).

The expression level of COPS6 was associated with the prognosis of patients with diverse types of cancer. To assess the relationship between COPS6 expression level and patient prognosis across various tumors, patients were divided into high and low COPS6 expression groups based on the median COPS6 expression level. Utilizing the GEPIA2 website, it was revealed that high expression level of COPS6 was significantly associated with poor OS in GBM (P = 0.017), KICH (P = 0.031), mesothelioma (MESO) (P = 0.0026), lower grade glioma (LGG) (P = 0.007), LIHC (P = 0.011), and LUAD (P = 0.018) (Figure 3A). Conversely, low expression level of COPS6 was correlated with poor DFS in KIRP (P = 0.042), while high expression level of COPS6 was associated with poor DFS in LGG (P = 0.0013), LIHC (P = 0.024), adrenocortical carcinoma (ACC) (P = 0.034), KIRC (P = 0.009), MESO (P = 0.0027), and stomach adenocarcinoma (STAD) (P = 0.049) (Figure 3B). Cox regression analysis indicated that COPS6 was a high-risk gene for OS in HNSC, KICH, KIRC, LGG, LIHC, and MESO (P < 0.05), while it was appeared as a low-risk gene for OS in BRCA (P < 0.05). Additionally, COPS6 was identified as a high-risk gene for DSS in KICH, KIRC, LGG, MESO, and READ (P < 0.05), as well as a low-risk gene for DSS in BRCA (P < 0.05). Moreover, COPS6 was found as a high-risk gene for PFI in ACC, LGG, LIHC, and STAD (P < 0.001), as well as a high-risk gene for PFI in KICH, KIRC, LGG, MESO, and STAD (P < 0.05), while a low-risk gene for PFI in BRCA (P < 0.05). These findings were derived from TCGA database using the survival and forestplot R package (Figure 3C). The association between COPS6 expression level and OS (Figure 4A), PFI (Figure 4B), DSS (Figure 4C), and DFI (Figure 4D) was further confirmed through Kaplan-Meier survival analysis in pan-cancer patients from TCGA database.

Differential expression analysis results of COPS6 in matched TCGA normal and Genotype-Tissue Expression data using the GEPIA2 website with specific cutoff criteria. The relationship between COPS6 expression level and immune infiltrating cells in TCGA tumors was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

Permutation test for the association between COPS6 expression level and immune infiltration was performed using the GEPIA2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

Correlation between COPS6 expression level and immune infiltration

The relationship between COPS6 expression level and immune-infiltrating cells in TCGA tumors was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

Correlation between COPS6 expression level and immune infiltration

The relationship between COPS6 expression level and immune-infiltrating cells in TCGA tumors was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

Correlation between COPS6 expression level and immune infiltration

The relationship between COPS6 expression level and immune-infiltrating cells in TCGA tumors was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.

Correlation between COPS6 expression level and immune infiltration

The relationship between COPS6 expression level and immune-infiltrating cells in TCGA tumors was examined using the TIMER2 website. Across multiple algorithms, a negative correlation was found between COPS6 expression level and CD8+ T cell infiltration in BRCA-LumA, HNSC, HNSC-HPV-, SKCM, SKCM-metastasis, and tenosynovial giant cell tumor (TGCT) (Figure 6A and B). Conversely, the correlation between cancer-associated fibroblast infiltration and COPS6 expression level exhibited heterogeneity. Negative correlations were identified in DLBCL, OV, SARC, THYM, and THCA.
Wang SL et al. COP56 in cancer progression

A

Protein expression of COP56 in Hepatocellular carcinoma

Protein expression of COP56 in colon cancer

Protein expression of COP56 in clear cell RCC

Protein expression of COP56 in UCEC

Protein expression of COP56 in lung adenocarcinoma

Protein expression of COP56 in lung squamous cell carcinoma

Protein expression of COP56 in head and neck squamous carcinoma

Protein expression of COP56 in pancreatic adenocarcinoma

P < 0.001

CPTAC samples

Normal (n = 165)
Primary tumor (n = 165)

Normal (n = 100)
Primary tumor (n = 97)

Normal (n = 84)
Primary tumor (n = 110)

Normal (n = 31)
Primary tumor (n = 100)

Normal (n = 111)
Primary tumor (n = 111)

Normal (n = 102)
Primary tumor (n = 110)

Normal (n = 71)
Primary tumor (n = 106)

Normal (n = 74)
Primary tumor (n = 137)
Wang SL et al. COPS6 in cancer progression

B

LUAD

F value = 4.82
Pr(>F) = 0.00257

KICH

F value = 8.19
Pr(>F) = 0.000112

Stage I Stage II Stage III Stage IV
Cancer: ESCA

Stage I Stage II Stage III Stage IV
Cancer: LUAD

F value = 5.07
Pr(>F) = 0.0018

LIHC

F value = 5.28
Pr(>F) = 0.00143

Stage I Stage II Stage III Stage IV
Cancer: LUSC

Stage I Stage II Stage III Stage IV
Cancer: KIRC

C

Age ≥ 65 < 65

8.4e-05

Age ≥ 65 < 65

0.0093
while positive correlations were found in HNSC, HNSC-HPV-, and TGCT (Figure 6C and D). The relationship between COPS6 expression level and macrophage infiltration varied depending on macrophage subtype. An inverse association was detected between COPS6 expression level and M1 macrophages, along with a positive association between COPS6 expression level and M2 macrophages in certain tumors (Figure 6E and F). For instance, in DLBCL, four algorithms demonstrated a negative association between COPS6 expression level and M1 macrophages, while TIDE algorithm revealed a positive association between COPS6 expression level and M2 macrophages. Moreover, in BRCA, KIRC, THCA, and THYM, the TIDE algorithm indicated a positive correlation between COPS6 expression level and M2 macrophages. In most of the tumors, NK cell infiltration exhibited a weak correlation with COPS6 expression level, and clear associations were found only in a few tumors (Figure 6G and H). For instance, in THCA and THYM, COPS6 expression level showed a negative correlation with NK cell infiltration. Further analysis of NK cell subtypes revealed a negative correlation between COPS6 expression level and activated NK cell infiltration, as well as a positive correlation between COPS6 expression level and resting NK cell infiltration.

**Enrichment analysis and correlation analysis of COPS6-associated genes**

To gain deeper insights into the molecular mechanisms involving COPS6 in growth and progression of tumors, the GEPIA2 website was employed to screen the top 100 COPS6-associated genes. Subsequently, the top 5 genes with the highest correlation coefficients were identified and summarized as follows: POLR2J (r = 0.69, P < 0.001), BUD31 (r = 0.65, P < 0.001), TAF6 (r = 0.66, P < 0.001), ALKBH4 (r = 0.62, P < 0.001), and POP7 (r = 0.61, P < 0.001) (Figure 7A and B). The PPI network analysis was performed using the STRING website, resulting in the establishment of a network of 35 node genes (Figure 7C). The intersection of COPS6-associated genes obtained from the GEPIA2 and STRING led to the identification of GPS1 and TCEB2 (Figure 7D). Furthermore, the genes derived from both databases were merged, resulting in the detection of a total of 135 COPS6-related genes. Subsequently, GO and KEGG pathway enrichment analyses were conducted (Figure 7E and F). The KEGG pathway analysis revealed that COPS6-associated genes were enriched in pathways, such as ubiquitin-mediated proteolysis, nucleotide excision repair, human immunodeficiency virus 1 infection, Parkinson’s disease, and circadian rhythm. The GO enrichment analysis indicated enrichment in the proteasomal protein catabolic process, proteasome-mediated ubiquitin-dependent protein catabolic process, protein modification by small protein removal, intrinsic apoptotic signaling pathway, protein de neddylation, COPS, Cullin-RING ubiquitin ligase (CRL) complex, SCF ubiquitin ligase complex, Cul4A-RING E3 ubiquitin ligase complex, Cullin family protein binding, ubiquitin-protein transferase activity, and ubiquitin-like protein transferase activity.

**DISCUSSION**

The COP9 signalosome (CSN) is a complex protein composed of eight subunits (CSN1-CSN8), participating in various physiological processes. The CSN1, 2, 3, 4, 7, and 8 subunits contain a percutaneous coronary intervention domain, which acts as a scaffold in CSN assembly, while the COPS6 and COPS5 subunits possess an Mpr1-Pad 1-N-terminal (MPN) domain[17]. COPS5 primarily exerts catalytic enzymatic activity, whereas COPS6, as an essential component of CSN, lacks the metal-binding site and isopeptidase activity associated with the COPS5 MPN domain. The precise function of COPS6 remains has still remained elusive[18]. COPS6 is involved in various processes, including the ubiquitin proteasome system, signal transduction, DNA damage response, and tumor progression. It exhibits a high expression...
Wang SL et al. COPS6 in cancer progression

Figure 3 Survival analysis of COP9 signalosome subunit 6. A: Overall survival (OS) and disease-free survival analysis conducted with the GEPIA2 website using the log-rank test ($P < 0.05$); B: Forest plots illustrating disease-specific survival (DSS), OS, progression-free interval (PFI), and disease-free interval (DFI) analyzed with Cox analysis in R software. ACC: Adrenocortical carcinoma; GBM: Glioblastoma multiforme; KICH: Kidney chromophobe; KIRP: Kidney renal papillary cell carcinoma; LGG: Lower grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; MESO: Mesothelioma; STAD: Stomach adenocarcinoma.

At present, there is a growing interest among researchers in investigating the role of COPS6 in tumors, as it has been shown to predominantly promote cancer. The CRLs are involved in the ubiquitination of Myc, and Fbxw7, a CRL component, which participates in Myc ubiquitination. In mouse experiments, Chen et al.[20] demonstrated that COPS6 enhances Fbxw7 degradation through binding, thereby maintaining Myc stability and promoting tumor progression. Additionally, in a mouse model, Zhao et al.[21] revealed that COPS6 overexpression in CRC is associated with a worse prognosis. Mechanistic studies suggested that ERK2 directly binds to CSN6 Leu163/Val165 and phosphorylates COPS6 at Ser148, thereby regulating β-Trcp and stabilizing β-catenin expression, consequently blocking the ubiquitin-proteasome pathway and promoting CRC development.

DOI: 10.5306/wjco.v14.i11.479 Copyright ©The Author(s) 2023.
Figure 4 Kaplan-Meier survival analysis of COP9 signalosome subunit 6 in the The Cancer Genome Atlas database performed in R software. A: Overall survival analysis. B: Progression-free interval analysis; C: Disease-specific survival analysis; D: Disease-free interval analysis. ACC: Adrenocortical carcinoma; BRCA: Breast invasive carcinoma; KIRC: Kidney renal clear cell carcinoma; LGG: Lower grade glioma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma. 

Programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) checkpoint blockade is an emerging immunotherapy modality in various tumors, while its regulatory mechanism remains uncertain. Su et al.[23] demonstrated that COP9 expression level could be regulated by the EGFR-ERK pathway, inhibiting PD-L1 degradation and maintaining PD-L1 stability in GBM. Additionally, several studies have reported the involvement of COP9 in the epithelial-mesenchymal transition process in various tumors, promoting tumor invasion and metastasis. For instance, Zhang et al.[24] revealed that the COP9-UBR5-CDK9 axis could control melanoma proliferation and metastasis, while Mao et al.[25] found that COP9 could promote migration and invasion of cervical cancer cells by regulating the expression level of cathepsin L through the autophagy-lysosomal system. Furthermore, COP9 was found to maintain the key transcription factor Snail1, promoting the invasion of breast cancer cells by inhibiting Snail1 ubiquitination[26].

While previous studies have highlighted the significant role of COP9 in the progression of specific tumors, the heterogeneity of tumors suggests potential variations in its function across different cancer types. Therefore, a comprehensive analysis and screening are necessary to validate existing findings and provide direction for the future COP9-related studies. In the present study, it was attempted to conduct comprehensive multilevel differential analysis and survival analysis of COP9 in pan-cancer data collected from various public databases and online analysis tools, including TCGA, GEO, CPTAC, GEPIA2, TIMER2, and UALCAN. The findings demonstrated that the expression level of the COP9 gene was significantly upregulated in the most types of cancer compared with normal tissues, except for KICH and LAML. Prognostic analysis revealed that the high expression level of COP9 was typically associated with worse prognosis in the majority of tumors, while showing a favorable prognosis in KIRP, BRCA, LUSC, and PCPG. Mutational analysis...
Wang SL et al. COP56 in cancer progression

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z
Some deficiencies in this study. For instance, only a multifaceted analysis of investigated the role of between levels, making them promising targets for future investigations. Additionally, a significant association was found and suggested a negative or no correlation with the M1 phenotype. However, it is noteworthy that in COPS6 were identified as the two genes exhibiting the strongest correlation. This indicates that COPS6 could inhibit CD8+ T cell infiltration within the tumor microenvironment (TME), thereby facilitating tumor immune evasion. Furthermore, a negative correlation was identified between COPS6 expression level and the M1 phenotype of tumor-associated macrophages (TAMs), while a positive correlation was found with the M2 phenotype. TAMs, which are macrophages that infiltrate tumor tissue and differentiate from monocytes, predominantly adopt the immunosuppressive M2 phenotype in the TME[29]. The present study revealed a positive correlation between COPS6 expression level and the M2 phenotype in the TIDE algorithm for DLBCL, BRCA, KIRC, THCA, THYM, and other tumors, while other algorithms exhibited a negative correlation with the M1 phenotype. However, it is noteworthy that in some tumors, only the TIDE algorithm yielded consistent results, while other algorithms suggested a negative or no correlation between COPS6 expression level and the M2 phenotype. This discrepancy could be attributed to variations in the statistical methods employed by each algorithm, necessitating further experimental validation of these findings.

There is a scarcity of research regarding the interaction between COPS6 Level and TME, highlighting the urgent need to explore the role of COPS6 in the TME. Furthermore, in the present study, correlation and enrichment analyses of COPS6 were conducted, and GPS1 and TCEB2 were identified as the two genes, exhibiting the strongest correlation. This investigation sheds light on the potential function and significance of COPS6 as a novel biomarker in cancer, setting the stage for further research on its molecular mechanisms and the development of targeted therapies. Moreover, the findings emphasize the importance of studying the COPS6-related TIME. However, it should be noted that the current study of COPS6 is preliminary, and the specific mechanisms of its action in different types of cancer remain elusive. Therefore, additional resources and efforts are warranted to delve deeper into the role of COPS6 in cancer.

The present study revealed a potential association of COPS6 with survival outcomes in various tumors. Notably, GPS1 and TCEB2 were identified as the two genes exhibiting the strongest correlation with COPS6 at both the gene and protein levels, making them promising targets for future investigations. Additionally, a significant association was found between COPS6 expression level and immune infiltration in diverse types of cancer, such as BRCA, HNSC, and TGCT, where research on the TIME remains limited.

CONCLUSION

This study is the first to explore the role of COPS6 in pan-cancer, taking full use of the existing public database to investigate COPS6 from the aspects of gene expression level, mutation, TIME, and prognosis. However, there are also some deficiencies in this study. For instance, only a multifaceted analysis of COPS6 was conducted through
Wang SL et al. COP56 in cancer progression

A

B

P > 0.05

P < 0.05

ACC (n=79)
BLCA (n=408)
BRCA (n=1100)
BRCA+Basal (n=394)
BRCA+Her2 (n=62)
BRCA+LumA (n=568)
BRCA+LumB (n=219)
CESC (n=306)
CHOL (n=36)
COAD (n=458)
ESCA (n=49)
EGFR (n=186)
GBM (n=153)
HNSC (n=522)
HNSC-HPV- (n=422)
HNSC-HPV+ (n=98)
KICH (n=66)
KIRP (n=332)
KIRP (n=290)
LGG (n=516)
LIHC (n=371)
LUAD (n=315)
LUAD (n=371)
LUSC (n=501)
MESO (n=87)
OV (n=303)
PAAD (n=179)
PCPG (n=179)
SARC (n=260)
SKCM (n=471)
SKCM_NOS (n=350)
SKCM_Tumor (n=301)
STAD (n=415)
TGCT (n=150)
THCA (n=509)
THYM (n=120)
UCEC (n=545)

Cor

1

0

-1

Purity

Infiltration level

COP56 expression level (log_10)

HNSC

Purity

Infiltration level

COP56 expression level (log_10)

HNSC-HPV-

Purity

Infiltration level

COP56 expression level (log_10)

SKCM

Purity

Infiltration level

COP56 expression level (log_10)

TGCT

Purity

Infiltration level

Correlation with T cell CD8+ TIMER

Rho = 0.288
p = 7.53e-17

Rho = 0.292
p = 2.60e-11

Correlation with T cell CD8+ EPIC

Rho = 0.343
p = 6.81e-07

Rho = 0.335
p = 5.81e-12

Correlation with T cell CD8+ naive_XCELL

Rho = 0.14
p = 2.62e-03

Rho = 0.249
p = 6.91e-08

Correlation with T cell CD8+ XCELL

Rho = 0.236
p = 3.60e-03

Rho = 0.448
p = 1.20e-05
Figure 6 Immune infiltration analysis of COP9 signalosome subunit 6 in the The Cancer Genome Atlas database using the TIMER2 website. A: Heatmap depicting the correlation between COP9 signalosome subunit 6 (COPS6) and CD8+ T cells; B: Scatter plot illustrating the relationship between COPS6 and CD8+ T cells; C: Heatmap displaying the correlation between COPS6 and cancer-associated fibroblasts; D: Scatter plot demonstrating the relationship between COPS6 and cancer-associated fibroblasts; E: Heatmap indicating the correlation between COPS6 and macrophages; F: Scatter plot showing the relationship between COPS6 and macrophages; G: Heatmap presenting the correlation between COPS6 and natural killer (NK) cells; H: Scatter plot depicting the relationship between COPS6 and NK cells. TPM: Transcripts per million.
Wang SL et al. COPS6 in cancer progression
bioinformatics, while no experiment was carried out to verify the results, hindering the generalization of the findings.

In conclusion, the present study provided early evidence that COPS6 could be associated with clinicopathological characteristics in various tumors and could play a role in several cancer hallmarks. Additional research is needed to further elucidate the role of COPS6 in cancer progression.

**ARTICLE HIGHLIGHTS**

**Research background**
The COP9 signaling body subunit 6 (COPS6) has been implicated in cancer progression, but its precise role in most types of cancer is unknown.

**Research motivation**
This study aimed to investigate the functional and clinical relevance of COPS6 in different tumor types, using publicly available databases.
**Research objectives**

This study hopes to provide a basis for COPS6 as a novel biomarker for cancer research by exploring the role of COPS6 in different cancer types.

**Research methods**

We used R software and online analysis databases to analyze the differential expression, prognosis, mutation and related functions of COPS6 in pan-cancer.

**Research results**

Differential expression analysis and survival analysis demonstrated that COPS6 was highly expressed and associated with high-risk profiles in the majority of cancer types. Missense mutations are the main type of COPS6 mutations, and in most types of cancer, the levels of COPS6 expression are positively correlated with tumor mutation burden and microsatellite instability. Immune infiltration analysis found COPS6 to play different roles in different cancers. Gene co-expression and enrichment analysis highlighted COPS6-related genes were predominantly involved in processes, such as ubiquitin-mediated proteolysis and human immunodeficiency virus 1 infection.

**Research conclusions**

This study provides early evidence that COPS6 may be associated with the clinicopathological features of various tumors and may play a role in several cancer features, providing a basis for subsequent studies related to COPS6.

**Research perspectives**

Since this study mainly focused on data analysis, subsequent studies required experimental validation of relevant results.

---

**FOOTNOTES**

**Co-first authors:** Shi-Lin Wang and Guang-Zheng Zhuo.

**Co-corresponding authors:** Yun-Bao Pan and Yi-Rong Li.

**Author contributions:** Pan YB designed the research; Wang SL and Zhuo GZ performed the research; Wang SL, Wang LP and Zhuo GZ contributed analytic tools; Wang SL and Zhuo GZ analyzed the data; Wang SL and Pan YB wrote the paper; Pan YB and Li YR were responsible for the supervision. Wang SL and Zhuo GZ contributed equally to this work as co-first authors. The reasons for designating Wang SL and Zhuo GZ as co-first authors are twofold. First, the research was performed as a collaborative effort, and the designation of co-corresponding authorship accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. Second, Wang SL and Zhuo GZ contributed an equally substantial effort throughout the study. They are principal principals of paper writing and data analysis, selecting these researchers as co-first authors, recognizing and respecting this equal contribution. Pan YB and Li YR contributed equally to this work as co-corresponding authors. The reasons for designating Pan YB and Li YR as co-corresponding authors are twofold. First, the research was performed as a collaborative effort. This ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, the overall research team encompassed authors with a variety of expertise and skills from different fields, and the designation of co-corresponding authors best reflects this diversity. Pan YB and Li YR, as heads of both groups, contributed substantially to the experimental design, data analysis and revision, and were therefore listed as co-corresponding authors.

**Supported by** National Natural Science Foundation of China, No. 31900558; the Hubei Provincial Youth Talents Program for Public Health, No. WSKJRC2022013; Wuhan Young and Middle-Aged Medical Backbone Talents Training Project, No. WHQG201904.

**Conflict-of-interest statement:** The authors have no relevant financial or non-financial interests to disclose.

**Data sharing statement:** Technical appendix, statistical code, and dataset available from the corresponding author at [panyunbao@outlook.com]. Participants gave informed consent for data sharing.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Yun-Bao Pan 0000-0002-6311-2945; Yi-Rong Li 0000-0002-7493-045X.

S-Editor: Lin C
L-Editor: Filipodia
P-Editor: Zhang XD
REFERENCES


